News

Alvotech and Dr. Reddy’s partner to co-develop biosimilar candidate for Keytruda (pembrolizumab)
Alvotech (NASDAQ:ALVO) and Dr. Reddy’s Laboratories (NYSE:RDY) have entered into a collaboration and license agreement to ...
NDTV Profit on MSN1h
Dr Reddy's, Alvotech Partner To Develop Biosimilar For Cancer Treatment
Dr Reddy's Laboratories on Thursday said it has joined hands with global biotech firm Alvotech to co-develop and ...
Dr. Reddy’s, Alvotech to co-develop, market biosimilar of Merck’s cancer drug Keytruda
Dr. Reddy's and Alvotech collaborate to develop biosimilar to Keytruda, enhancing oncology capabilities and global reach.
Urology Times4d
Adjuvant pembrolizumab continues to show DFS, OS benefits for ccRCC at 5-year assessment
"These long-term results continue to support [pembrolizumab's] use as a standard of care for patients at increased risk of ...
Healio3d
Sacituzumab govitecan combo may be ‘new first-line standard of care’ in breast cancer subset
First-line treatment with sacituzumab govitecan plus pembrolizumab showed significant improvement in PFS vs. chemotherapy ...
MedPage Today on MSN4d
First-Line Keytruda-Trodelvy Boosts PFS in Triple-Negative Breast Cancer
CHICAGO -- Combining pembrolizumab (Keytruda) with sacituzumab govitecan (SG, Trodelvy) instead of chemotherapy as first-line ...
Pre-surgical combination therapy boosts survival in patients with rare thyroid cancer
A pre-surgical combination therapy including pembrolizumab plus dabrafenib and trametinib (DTP) significantly improved ...
Good News Network4d
Grandfather Diagnosed With Stage Four Lung Cancer Becomes Free of Disease After Immunotherapy
A grandad diagnosed with stage 4 lung cancer–one of the deadliest—has become disease-free after being treated with an ...
Targeted Oncology1d
New Standard of Care With Pembrolizumab and CRT in Cervical Cancer
Linda Duska, MD, FASCO, MPH, discusses the importance of the KEYNOTE-A18 study reinforcing the new standard of care of pembrolizumab plus concurrent chemoradiotherapy in locally advanced cervical ...
Cancer Therapy Advisor2d
Sacituzumab Govitecan and Pembrolizumab: A New First-Line Standard for Advanced TNBC?
Sacituzumab govitecan plus pembrolizumab improves outcomes vs chemotherapy plus pembrolizumab in patients with previously untreated, PD-L1+ TNBC.
Medscape4d
Sacituzumab or Chemo in First-Line TNBC: Which Is Better?
Pembrolizumab with sacituzumab govitecan instead of chemotherapy led to improved progression-free survival in PD-L1-postive ...
Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...